Benmoxin

DB09246ApprovedWithdrawnSmall molecule

Benmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was first synthesized in 1967 and rapidly used in Europe as an antidepressant. However, this... However, this agent is no longer marketed.

Primary indication: For the treatment of depression.Curator reviewed
Formula / weight: C₁₅H₁₆N₂O · 240.306 g/mol (avg)
Also known as: Mebamoxine

Resolves to

Compound

UNIIXC9FY2SGBGCAS7654-03-7ChEMBLCHEMBL1877495ChEBI134978PubChem71671

Structure

InChIKeyBEWNZPMDJIGBED-UHFFFAOYSA-NSMILESCC(NNC(=O)C1=CC=CC=C1)C1=CC=CC=C1

What you can answer from here — as of March 06, 2025

1,331Drug interactionsStructured to mechanism, not free text

Which companies are running trials of Benmoxin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account